(Reuters) - Last month, U.S. prescriptions of the company's second biggest-selling drug, Avandia for diabetes, increased 6 percent after a difficult period of lacklustre growth and past manufacturing problems.
But an article on Monday in the prestigious New England Journal of Medicine by one of the world's top cardiologists suggesting the medicine increased the risk of heart death by 64 percent and the risk of heart attack by 43 percent will throw that positive trend into reverse.
Read more at Reuters.com Business News
But an article on Monday in the prestigious New England Journal of Medicine by one of the world's top cardiologists suggesting the medicine increased the risk of heart death by 64 percent and the risk of heart attack by 43 percent will throw that positive trend into reverse.
Read more at Reuters.com Business News
No comments:
Post a Comment